People In Brief
This article was originally published in The Tan Sheet
Executive Summary
CHPA scientists Schneider, Roehrig exit
You may also be interested in...
In Brief
Acura delays Nexafed post meth studies
Valeant Deal Would Aid Afexa’s Cold-FX Expansion Plans
Valeant Pharmaceuticals International’s acquisition of Afexa Health Sciences likely will boost efforts to transition Afexa’s Cold-FX from a Canadian natural health product to a U.S. pharmaceutical.
H&P/Triad Stops OTC Manufacturing In Consent Decree With FDA
FDA forbids Triad Group, H&P Industries and three employees from manufacturing or distributing OTC products until they comply with good manufacturing practices.